Brought to you by 
Melinta enters financing agreement with Oberland Capital
30 Jun 2017
Executive Summary
Infectious disease-focused Melinta Therapeutics Inc. entered into a loan and securities financing agreement with Oberland Capital Management in which Melinta is eligible to receive up to $90mm in equity and debt. Most of the funding was received upon the recent FDA approval of the NDAs for Baxdela (delafloxacin) in treating acute bacterial skin and skin structure infections. The company can draw down funds in three additional tranches. Melinta will use the funds to commercialize Baxdela.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Melinta enters financing agreement with Oberland Capital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice